BIIB Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 9.89% compared to Biogen's net margin of 50.24%. Biogen's return on equity of 9.11% beat Johnson & Johnson's return on equity of 30.18%.

Biogen has a consensus price target of $171.95, signalling upside risk potential of 29.96%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 7.99%. Given that Biogen has higher upside potential than Johnson & Johnson, analysts believe Biogen is more attractive than Johnson & Johnson.

Biogen has a beta of 0.144, which suggesting that the stock is 85.631% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.846%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.2% to investors and pays a quarterly dividend of $1.30 per share. Biogen pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen quarterly revenues are $2.4B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Biogen's net income of $240.5M is lower than Johnson & Johnson's net income of $11B. Notably, Biogen's price-to-earnings ratio is 13.06x while Johnson & Johnson's PE ratio is 17.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.97x versus 4.25x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 9.89% compared to Biogen's net margin of 21.68%. Biogen's return on equity of 9.11% beat Eli Lilly and's return on equity of 78.25%.

Biogen has a consensus price target of $171.95, signalling upside risk potential of 29.96%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 17.23%. Given that Biogen has higher upside potential than Eli Lilly and, analysts believe Biogen is more attractive than Eli Lilly and.

Biogen has a beta of 0.144, which suggesting that the stock is 85.631% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.404, suggesting its less volatile than the S&P 500 by 59.63%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.69% to investors and pays a quarterly dividend of $1.50 per share. Biogen pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen quarterly revenues are $2.4B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Biogen's net income of $240.5M is lower than Eli Lilly and's net income of $2.8B. Notably, Biogen's price-to-earnings ratio is 13.06x while Eli Lilly and's PE ratio is 66.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.97x versus 14.97x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 9.89% compared to Biogen's net margin of 32.71%. Biogen's return on equity of 9.11% beat Merck &'s return on equity of 39.02%.

Biogen has a consensus price target of $171.95, signalling upside risk potential of 29.96%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 24.4%. Given that Biogen has higher upside potential than Merck &, analysts believe Biogen is more attractive than Merck &.

Biogen has a beta of 0.144, which suggesting that the stock is 85.631% less volatile than S&P 500. In comparison Merck & has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.863%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.86% to investors and pays a quarterly dividend of $0.81 per share. Biogen pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen quarterly revenues are $2.4B, which are smaller than Merck & quarterly revenues of $15.5B. Biogen's net income of $240.5M is lower than Merck &'s net income of $5.1B. Notably, Biogen's price-to-earnings ratio is 13.06x while Merck &'s PE ratio is 11.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.97x versus 3.25x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 9.89% compared to Biogen's net margin of -907.48%. Biogen's return on equity of 9.11% beat Moderna's return on equity of -29.23%.

Biogen has a consensus price target of $171.95, signalling upside risk potential of 29.96%. On the other hand Moderna has an analysts' consensus of $47.64 which suggests that it could grow by 74.17%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

Biogen has a beta of 0.144, which suggesting that the stock is 85.631% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.4B, which are larger than Moderna quarterly revenues of $107M. Biogen's net income of $240.5M is higher than Moderna's net income of -$971M. Notably, Biogen's price-to-earnings ratio is 13.06x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.97x versus 3.39x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.